Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;101(2):297-307.
doi: 10.1007/s00277-021-04712-8. Epub 2021 Dec 2.

Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement

Affiliations

Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement

Danika Di Giacomo et al. Ann Hematol. 2022 Feb.

Abstract

Platelet-derived growth factor receptor B (PDGFRB) gene rearrangements define a unique subgroup of myeloid and lymphoid neoplasms frequently associated with eosinophilia and characterized by high sensitivity to tyrosine kinase inhibition. To date, various PDGFRB/5q32 rearrangements, involving at least 40 fusion partners, have been reported. However, information on genomic and clinical features accompanying rearrangements of PDGFRB is still scarce. Here, we characterized a series of 14 cases with a myeloid neoplasm using cytogenetic, single nucleotide polymorphism array, and next-generation sequencing. We identified nine PDGFRB translocation partners, including the KAZN gene at 1p36.21 as a novel partner in a previously undescribed t(1;5)(p36;q33) chromosome change. In all cases, the PDGFRB recombination was the sole cytogenetic abnormality underlying the phenotype. Acquired somatic variants were mainly found in clinically aggressive diseases and involved epigenetic genes (TET2, DNMT3A, ASXL1), transcription factors (RUNX1 and CEBPA), and signaling modulators (HRAS). By using both cytogenetic and nested PCR monitoring to evaluate response to imatinib, we found that, in non-AML cases, a low dosage (100-200 mg) is sufficient to induce and maintain longstanding hematological, cytogenetic, and molecular remissions.

Keywords: Chromosome translocations; Imatinib; KAZN; Molecular monitoring; PDGFRB.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Cytogenetic and molecular characterization of the novel KAZN::PDGFRB fusion. a FISH break-apart assay with fosmids WI2-0883F15 (spectrum green) and WI2-0968K05 (spectrum orange) for KAZN/1p36.21 showed a fusion signal on normal chromosome 1, a red signal on der(1), and a green signal on der(5) in case no. 14 (Table 1). b Direct sequencing showed an in-frame fusion joining exon 4 of KAZN to exon 12 of PDGFRB. GenBank accession numbers: NM_201628.3 for KAZN and NM_002609.3 for PDGFRB. nl, normal; ex, exon
Fig. 2
Fig. 2
The mutational background of PDGFRB-positive cases. Oncoprint heatmap showing mutations found at diagnosis in cases with a rearrangement of PDGFRB. Somatic mutations are reported in red and germline mutations in green; gray, non-mutated genes

References

    1. Ondrejka SL, Jegalian AG, Kim AS, Chabot-Richards DS, Giltnane J, Czuchlewski DR, Shetty S, Sekeres MA, Yenamandra A, Head D, Jagasia M, His ED. PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin. Haematologica. 2014;99:e148–e151. doi: 10.3324/haematol.2014.105452. - DOI - PMC - PubMed
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France
    1. Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol. 2017;96:1463–1470. doi: 10.1007/s00277-017-3067-x. - DOI - PubMed
    1. Fang H, Tang G, Loghavi S, Greipp P, Wang W, Verstovsek S, Medeiros LJ, Reichard KK, Miranda RN, Wang SA. Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms. Histopathology. 2020;76:1042–1054. doi: 10.1111/his.14097. - DOI - PubMed
    1. Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JH, Varley KE, Toydemir RM, Deininger MW, Raetz EA, O'Hare T. A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica. 2018;103:e87–e91. doi: 10.3324/haematol.2017.165282. - DOI - PMC - PubMed

Substances